Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Rasmussen's encephalitis (RE) stands as a rare neurological disorder marked by progressive cerebral hemiatrophy and epilepsy resistant to medical treatment. Despite extensive study, the primary cause of RE remains elusive, while its histopathological features encompass cortical inflammation, neuronal degeneration, and gliosis. The underlying molecular mechanisms driving disease progression remain largely unexplored. In this case study, we present a patient with RE who underwent hemispherotomy and has remained seizure-free for over six months, experiencing gradual motor improvement. Furthermore, we conducted molecular analysis on the excised brain tissue, unveiling a decrease in the expression of cell-cycle-associated genes coupled with elevated levels of BDNF and TNF-α proteins. These findings suggest the potential involvement of cell cycle regulators in the progression of RE.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11313535PMC
http://dx.doi.org/10.3390/ijms25158487DOI Listing

Publication Analysis

Top Keywords

brain tissue
8
case report
4
report molecular
4
molecular analyses
4
analyses cell-cycle-related
4
cell-cycle-related genes
4
genes cortical
4
cortical brain
4
tissue patient
4
patient rasmussen
4

Similar Publications

This study introduces a novel optimization framework for cranial three-dimensional rotational angiography (3DRA), combining the development of a brain equivalent in-house phantom with Figure of Merit (FOM) a quantitative evaluation method. The technical contribution involves the development of an in-house phantom constructed using iodine-infused epoxy and lycal resins, validated against clinical Hounsfield Units (HU). A customized head phantom was developed to simulate brain tissue and cranial vasculature for 3DRA optimization.

View Article and Find Full Text PDF

ACP-105 (CAS: 1048998-11-3) is a novel non-steroidal selective androgen receptor modulator (SARM), increasingly detected in anti-doping analyses, yet lacking a comprehensive ADME profile. This study provides the first integrative in silico characterization of ACP-105's ADME properties using seven independent methods (ADMETlab 3.0, ADMET Predictor 12.

View Article and Find Full Text PDF

Identification and prioritization of gene sets associated with schizophrenia risk by network analysis.

Psychopharmacology (Berl)

September 2025

Institute of Cardiovascular Research, Sleep Medical Center, Department of Psychiatry, Fundamental and Clinical Research on Mental Disorders Key Laboratory of Luzhou, Affiliated Hospital, Southwest Medical University, Luzhou, Sichuan Province, 646000, China.

Rationale: Genome-wide association studies (GWASs) are used to identify genetic variants for association with schizophrenia (SCZ) risk; however, each GWAS can only reveal a small fraction of this association.

Objectives: This study systematically analyzed multiple GWAS data sets to identify gene subnetwork and pathways associated with SCZ.

Methods: We identified gene subnetwork using dmGWAS program by combining SCZ GWASs and a human interaction network, performed gene-set analysis to test the association of gene subnetwork with clinical symptom scores and disease state, meanwhile, conducted spatiotemporal and tissue-specific expression patterns and cell-type-specific analysis of genes in the subnetwork.

View Article and Find Full Text PDF

Mice lacking caveolin-1 (), a major protein of the lipid raft of plasma membrane, show deregulated cellular proliferation of the mammary gland and an abnormal fetoplacental communication during pregnancy. This study leverages a multi-omics approach to test the hypothesis that the absence of elicits a coordinated crosstalk of genes among the mammary gland, placenta and fetal brain in pregnant mice. Integrative analysis of metabolomics and transcriptomics data of mammary glands showed that the loss of significantly impacted specific metabolites and metabolic pathways in the pregnant mice.

View Article and Find Full Text PDF

Background: To assess the efficacy and safety of tenecteplase in patients presenting within 24 hours of symptom onset with a large vessel occlusion and target mismatch on perfusion computed tomography.

Methods: ETERNAL-LVO was a prospective, randomized, open-label, blinded end point, phase 3, superiority trial where adult participants with a large vessel occlusion, presenting within 24 hours of onset with salvageable tissue on computed tomography perfusion, were randomized to tenecteplase 0.25 mg/kg or standard care across 11 primary and comprehensive stroke centers in Australia.

View Article and Find Full Text PDF